Gilead’s Biktarvy shows durable viral suppression in HIV-1 trial
Gilead Sciences has reported that new long-term data from open-label extensions (OLE) of two Phase...
Gilead Sciences has reported that new long-term data from open-label extensions (OLE) of two Phase...
Merck and Ridgeback Biotherapeutics have reported preliminary results from a Phase IIa trial of investigational...
Eli Lilly and Company has reported that results from the SURPASS-2 clinical trial of tirzepatide...
COSELA™ (trilaciclib) is the first approved myeloprotection therapy indicated to reduce the occurrence of chemotherapy-induced...
Dicerna Pharmaceuticals and Roche have commenced the Phase II combination trial of investigational GalXC RNAi...
Marker Therapeutics has treated the first patient in its Phase II trial of its lead...
Eli Lilly and Company and Incyte have reported positive top-line results from Phase III BRAVE-AA2...
Vir Biotechnology and GlaxoSmithKline (GSK) have reported that the independent Data and Safety Monitoring Board...
Amgen has reported positive data from the Phase III study of BLINCYTO (blinatumomab) in paediatric...
On 1 March, Merck announced the voluntary withdrawal of its Keytruda (pembrolizumab) immunotherapy for the...